Singapore markets open in 2 hours 12 minutes

BCRX Jan 2024 30.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.1500+0.3400 (+41.98%)
As of 11:25AM EDT. Market open.
Full screen
Loading interactive chart…
  • Zacks

    Has Alignment Healthcare (ALHC) Outpaced Other Medical Stocks This Year?

    Here is how Alignment Healthcare (ALHC) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

  • Motley Fool

    BioCryst Pharmaceuticals (BCRX) Q2 2022 Earnings Call Transcript

    At this time, [Operator instructions] I will now turn the call over to your host, Mr. John Bluth at BioCryst. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; chief medical officer, Dr.

  • Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

    Shares of the rare disease specialist BioCryst Pharmaceuticals (NASDAQ: BCRX) were up by a noteworthy 20% on heavy volume at 9:38 a.m. ET Thursday morning. Although the biotech reported encouraging 2022 second-quarter results prior to today's opening bell, the real needle mover here appears to be the news that the Food and Drug Administration (FDA) has lifted the partial clinical hold on BCX9930. BCX9930 is an oral Factor D inhibitor indicated for a rare blood disease known as paroxysmal nocturnal hemoglobinuria (PNH).